Efficacy of TachoSil patches in controlling Dacron suture-hole bleeding after abdominal aortic aneurysm open repair.
OBJECTIVE
The aim of this study is evaluate the efficacy of TachoSil patches in controlling suture-hole bleeding after elective infrarenal abdominal aortic aneurysm (AAA) replacement with Dacron graft.


METHODS
Patients undergoing elective replacement of infrarenal AAA with Dacron grafts were prospectively randomized to TachoSil patches (Group I) or standard compression with surgical swabs (Group II).We evaluated time to haemostasis, blood loss during the operation, blood loss after cross-clamp removal, duration of operation, drain volume, requirement for blood transfusion and surgeons rating of efficacy.


RESULTS
Twenty patients were randomized (10 patients in each treatment Group). The mean time to haemostasis was 264 +/- 127.1 s (range: 180-600 s) in Group I and 408 +/- 159.5 s (range: 120-720 s) in Group II (p = 0.026); mean blood loss during the operation was 503.5 +/- 20.7 cc (range: 474-545 cc) in Group I and 615.7 +/- 60.3 cc (range: 530-720 cc) in Group II (p < 0.001); mean blood loss after cross-clamp removal was 26.5 +/- 4 g (range: 22-34 g) in Group I and 45.4 +/- 4.6 (range: 38-52 g) in Group II (p < 0.001) and mean drain volume was 116.7 +/- 41.4 cc (range: 79-230 cc) in Group I and 134.5 +/- 42.8 cc (range: 101-250 cc) in Group II (p = 0.034). There were no serious adverse events associated with use of TachoSil patches.


CONCLUSIONS
For patients undergoing aortic reconstruction with Dacron grafts, TachoSil patches were found to be safe and effective for the control of suture-hole bleeding.
Bajardi
Guido
G
Vascular Surgery Unit - University of Palermo, 90100 Palermo, Italy. guidobajardi@libero.it
Pecoraro
Felice
F
Mirabella
Domenico
D
D000368:Aged; D000369:Aged, 80 and over; D017544:Aortic Aneurysm, Abdominal / Q000601:surgery*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D019917:Blood Vessel Prosthesis Implantation / Q000295:instrumentation / Q000379:methods; D004338:Drug Combinations; D005260:Female; D005340:Fibrinogen / Q000627:therapeutic use*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013537:Sutures / Q000009:adverse effects*; D013917:Thrombin / Q000627:therapeutic use*; D016896:Treatment Outcome
D004338:Drug Combinations; D006490:Hemostatics; C518955:TachoSil; D005340:Fibrinogen; D013917:Thrombin